The transition back to a Trump administration signals potential shifts in the trajectory of value-based care, carrying implications for reimbursement models, Medicare, and industry consolidation. Here, the central objective remains to manage burgeoning health-care costs while improving patient outcomes, though approaches may diverge from those under the Biden administration. The Affordable Care Act (ACA), enacted over a decade ago, laid the groundwork for this transformation by fostering a shift from fee-for-service models to those emphasizing value and quality.
Medicare, as the nation’s largest health-care payer, plays a pivotal role in this policy arena. It accounted for $1 trillion, or 21% of national health-care expenditures, in 2023, as reported by the Centers for Medicare and Medicaid Services. Under a potential Trump comeback, initiatives like the Global and Professional Direct Contracting Model could become focal points once more, with possible modifications to align with previous goals, alongside an enhanced emphasis on choice and care options.
The Medicare Advantage program, which has drawn significant enrollment, stands to experience further evolution. Projections suggest that more than half of Medicare beneficiaries could adopt these plans by 2025, posing questions about competition dynamics with private plans and the possibility of switching preference to Medicare Advantage as the default. Policies pertaining to reimbursement, oversight, and flexibility could alter with a Trump reentry, potentially steering growth in enrollment and risk models.
- Strategic alignment across Medicare, Medicaid, and commercial offerings could streamline value-based care further, encouraging expansion within self-insured markets.
The intricate dance of integration and consolidation prompted by the ACA might face reduced regulatory scrutiny at the federal level, contingent on the state of individual states’ regulations. This could open avenues for further consolidation, a necessity for achieving cost efficiencies inherent in value-based models. However, the Trump administration may scale back federal efforts to ensure health equity within these models, shifting focus towards care price transparency.
For those with vested interests in health-care policy, such as large corporations and significant law firms, these anticipated changes underscore the necessity of vigilance and preparedness as the landscape continues to evolve under political influence.